Drug Trial Radar · NCT01797965
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,501
Actual
Start
Feb 15, 2013
Primary completion
Sep 24, 2018
Study completion Sep 24, 2018
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Feb 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis (RRMS) who completed Study 205MS301 (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318). Secondary objectives of this study in this study population are as follows: To describe MS-related outcomes, including MS relapse, disability progression, MS lesion formation, and participant-reported impact of MS, following long-term treatment with DAC HYP To assess the long-term immunogenicity of DAC HYP administered by prefilled syringe (PFS) To assess the safety, tolerability, and efficacy of switching to DAC HYP in participants previously on long-term treatment with interferon β-1a (Avonex) in Study 205MS301(NCT01064401).
Conditions
- Relapsing-Remitting Multiple Sclerosis
- Multiple Sclerosis
Interventions
BIIB019 (Daclizumab)Drug
Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: First dose of study drug in Study 303 to within 180 days of last dose (up to approximately 5.5 years)
Locations
222 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Little Rock, Arkansas
Research Site
La Jolla, California
Research Site
Aurora, Colorado
Research Site
Centennial, Colorado
Research Site
Naples, Florida
Research Site
Pompano Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Fort Wayne, Indiana
Research Site
Indianapolis, Indiana
Research Site
Kansas City, Kansas
Research Site
Lexington, Kentucky
Research Site
Wellesley, Massachusetts
Research Site
Worcester, Massachusetts
Research Site
Farmington Hills, Michigan
Research Site
Lebanon, New Hampshire
Research Site
Albuquerque, New Mexico
Research Site
Buffalo, New York
Research Site
Latham, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Rochester, New York
Research Site
Charlotte, North Carolina
Research Site
Raleigh, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Dayton, Ohio
Research Site
Medford, Oregon
Research Site
Portland, Oregon
Research Site
Allentown, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Cordova, Tennessee
Research Site
Franklin, Tennessee
Research Site
Knoxville, Tennessee
Research Site
Round Rock, Texas
Research Site
Henrico, Virginia
Research Site
Tacoma, Washington
Research Site
Milwaukee, Wisconsin
Research Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Showing 40 of 222 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.